As Castellani Takes PhRMA's Helm, Where Does Personalized Medicine Advocacy Stand? | GenomeWeb

Originally published Aug. 10.

By Turna Ray

The resignation of Billy Tauzin as the head of the Pharmaceutical Research and Manufacturers of America may be welcomed by those in the drug industry who feel he failed to represent the interests of drugmakers during healthcare reform. However, the former congressman from Louisiana and outspoken cancer survivor will certainly be missed by personalized medicine advocates for his vocal support of their cause.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.